Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1750-1756

  Ploussard, Guillaume ^b   Staerman, Frédéric ^a   Pierrevelcin, Jean ^a   Saad, Rodrigue ^b   Beauval, Jean Baptiste ⁱ   Roupret, Morgan ^c   Audenet, François ^c   Peyromaure, Mickaël ^d   Delongchamps, Nicolas Barry ^d   Vincendeau, Sébastien ^e   Fardoun, Tarek ^e   Rigaud, Jérôme ^f   Villers, Arnauld ^g   Bastide, Cyrille ^h   Soulie, Michel ⁱ   Salomon, Laurent ^b  

^a Robert Debré Academic Hospital   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Institut Cochin   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h HÔPITAL NORD   (France)

ⁱ CHU RANGUEIL   (France)

Author keywords

Prostate; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Salvage therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMISTRY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; SEMINAL VESICLE; SURVIVAL RATE; TREATMENT FAILURE; TUMOR INVASION; VELOCITY;

EID: 84888640542     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.04.073     Document Type: Article

References (28)

1. Doherty AP, Bower M, Smith GL et al: Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000; 83: 1432.
2. Shen S, Lepor H, Yaffee R et al: Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005; 173: 777.
3. Sengupta S, Christensen CM, Zincke H et al: Detectable prostate-specific antigen level between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol 2006; 176: 559.
4. Pound CR, Partin AW, Eisenberger MA et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591.
5. Rogers CG, Khan MA, Craig Miller M et al: Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004; 101: 2549.
6. Godoy G, Tareen BU and Lepor H: Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? Urology 2009; 74: 167.
7. Moreira DM, Presti JC Jr, Aronson WJ et al: Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol 2009; 182: 2250.
8. Naselli A, Introini C, Andreatta R et al: Prognostic factors of persistently detectable PSA after radical prostatectomy. Int J Urol 2009; 16: 82.
9. Semjonow A, Hamm M and Rathert P: Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 1993; 11: 218.
10. Ravery V: The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 1999; 17: 127.
11. Paul R, Hoppmann M, van Randenborgh H et al: Residual benign prostatic glands at the urethrovesical anastomosis after radical retropubic prostatectomy: prediction and impact on disease outcome. Eur Urol 2004; 46: 321.
12. Shah O, Melamed J and Lepor H: Analysis of apical soft tissue margins during radical retropubic prostatectomy. J Urol 2001; 165: 1943.
13. Wood DP Jr, Peretsman SJ and Seay TM: Incidence of benign and malignant prostate tissue in biopsies of the bladder neck after a radical prostatectomy. J Urol 1995; 154: 1443.
14. Moul JW: Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 2003; 21: 292.
15. Amling CL, Bergstralh EJ, Blute ML et al: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146.
16. Freedland SJ, Humphreys EB, Mangold LA et al: Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25: 1765.
17. Zietman AL, Dallow KC, McManus PA et al: Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 1996; 47: 236.
18. Small AC, Gong Y, Oh WK et al: The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol 2012; 188: 21.
19. Briganti A, Abdollah F, Nini A et al: Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 2011; 61: 1132.
20. Budiharto T, Joniau S, Lerut E et al: Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusionweighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011; 60: 125.
21. van der Poel HG, Buckle T, Brouwer OR et al: Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 2011; 60: 826.
22. Heesakkers RA, Hövels AM, Jager GJ et al: MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008; 9: 850.
23. Jadvar H: Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol 2012; 199: 278.
24. Sardana G, Dowell B and Diamandis EP: Emerging biomarkers for diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54: 1951.
25. Fradet Y: Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 2009; 19: 243.
26. Fiorentino M, Capizzi E and Loda M: Blood and tissue biomarkers in prostate cancer: State of the art. Urol Clin N Am 2010; 37: 131.
27. Ploussard G and de la Taille A: Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7: 101.
28. Kristiansen G: Diagnostic and prognostic biomarkers for prostate cancer. Histopathology 2012; 60: 125.